These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37848671)

  • 21. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cuproptosis in microsatellite stable colon cancer cells affects the cytotoxicity of CD8
    Zeng J; Chen H; Liu X; Xia H; Chen L; Lin D; Wang N; Weng C; Guan G; Zheng Y
    Chem Biol Interact; 2024 Nov; 403():111239. PubMed ID: 39306268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stromal Cell PD-L1 Inhibits CD8
    O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
    Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
    Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
    Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 29. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
    Khan B; Chen M; Wang H; Khan A; Hussain S; Shi J; Yang L; Hou Y
    Eur J Pharmacol; 2024 Jun; 972():176565. PubMed ID: 38599309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.
    Cecil DL; Gad EA; Corulli LR; Drovetto N; Lubet RA; Disis ML
    Cancer Prev Res (Phila); 2022 Apr; 15(4):225-231. PubMed ID: 34987061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
    Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
    Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression.
    Li B; Wang B
    Immunol Invest; 2022 Oct; 51(7):1921-1937. PubMed ID: 35852892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.